1. Scrip

Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

 
• By John Davis

Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.

R Francis
Sandoz CEO Richard Francis • Source: Sandoz.

Sandoz appears to have taken the lead in the close race to develop a biosimilar version of Roche's blockbuster TNF-inhibitor MabThera (rituximab) for Europe, announcing May 24 that the European Medicines Agency had accepted its regulatory submission for its biosimilar rituximab (GP2013).

The Novartis AG division has conducted pivotal confirmatory safety, pharmacokinetic/pharmacodynamic and efficacy studies of its biosimilar version of rituximab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.